問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

蕭樑材Hsiao, Liang-Tsai
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

Recruiting Trial

55Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蕭樑材

List

122Cases

2009-09-08 - 2011-06-22

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2007-11-01 - 2009-03-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-11-01 - 2012-11-30

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-07-20 - 2025-05-20

Phase III

A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

  • Condition/Disease

    Lymphoma, Non-Hodgkin

  • Test Drug

    BAY 80-6946 (copanlisib)；phosphatidylinositol 3-kinase (PI3K) inhibitor

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2015-05-01 - 2018-12-19

Phase III

A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2

  • Condition/Disease

    indolent non-Hodgkin’s lymphoma (iNHL)

  • Test Drug

    BAY 80-6946

Participate Sites
2Sites

Terminated2Sites

2015-06-30 - 2017-12-31

Phase IV

A post marketing surveillance study of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever

  • Condition/Disease

    neutropenic

  • Test Drug

    amphotericin B

Participate Sites
10Sites

Terminated9Sites

李文生
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Infectious Disease

2011-08-01 - 2014-01-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2010-03-06 - 2011-09-27

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-05-01 - 2020-08-17

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-08-12 - 2026-04-14

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB